Biomarkers in ANCA-Associated Vasculitis

Part of the following topical collections:
  1. Topical Collection on Vasculitis


Despite recent advances in the treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), relapse remains common and patients often experience a variable clinical course after initial treatment. New biomarkers are needed to aid the management of these complex diseases. Discoveries regarding the pathogenesis of AAV, from the importance both of activated B and T cells and the alternative complement pathway to genomic data, may lay the groundwork for identification of novel biomarkers.


ANCA AAV ANCA-associated vasculitis Biomarkers Granulomatosis with polyangiitis Wegener’s granulomatosis Microscopic polyangiitis Complement 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med. 2007;120(7):643. e9–14.PubMedCrossRefGoogle Scholar
  2. 2.
    Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener’s granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116:488–98.PubMedCrossRefGoogle Scholar
  3. 3.
    The WGET Research Group. Etanercept in addition to standard therapy in patients with Wegener’s granulomatosis. N Engl J Med. 2005;352:19–29.CrossRefGoogle Scholar
  4. 4.
    Finkielman JD, Merkel PA, Schroeder D, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med. 2007;147(9):611–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Girard T, Mahr A, Noel LH, et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener’s granulomatosis? A prospective study. Rheumatology (Oxford). 2001;40:147–51.CrossRefGoogle Scholar
  6. 6.
    Al K, Csemok E, Munch D, et al. Use of highly sensitive C-reactive protein for followup of Wegener’s granulomatosis. J Rheumatol. 2010;37:2319–25.CrossRefGoogle Scholar
  7. 7.
    Stone JH, Rajapakse VN, Hoffman GS, et al. A serum proteomic approach to gauging state of remission in Wegener’s granulomatosis. Arthritis Rheum. 2005;52(3):902–10.PubMedCrossRefGoogle Scholar
  8. 8.
    • Monach PA, Warner RL, Tomasson G. Serum proteins reflecting inflammation, injury, and repair as biomarkers of disease activity in ANCA-associated vasculitis. Ann Rheum Dis. 2012;0:1–9. Recently published study using serum repository from the RAVE study, which investigates several circulating proteins as candidate biomarkers.Google Scholar
  9. 9.
    Falk RJ, Terrell RS, Charles LA, et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990;87:4115–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110:955–63.PubMedGoogle Scholar
  11. 11.
    Birck R, Schmitt WH, Kaelsch. Serial ANCA determinations for monitoring disease activity in patients with ANCA-Associated vasculitis: systematic review. Am J Kidney Dis. 2006;47(1):15–23.PubMedCrossRefGoogle Scholar
  12. 12.
    • Tomasson G, Grayson PC, Mahr AD, et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-a meta-analysis. Rheumatology (Oxford). 2012;51(1):100–9. A meta-analysis of nine studies of the increase in ANCA titer and nine studies of persistent ANCA positivity, with calculated pooled likelihood ratios..CrossRefGoogle Scholar
  13. 13.
    Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 2000;43(9):2025–33.PubMedCrossRefGoogle Scholar
  14. 14.
    Jayne D, Rasmussen N, Andrassy K, et al. European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44.PubMedCrossRefGoogle Scholar
  15. 15.
    Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides. The role of ANCA specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64(10):3452–62.PubMedCrossRefGoogle Scholar
  16. 16.
    Espy C, Morelle W, Kavian N, et al. Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener’s). Arthritis Rheum. 2011;63(7):2105–15.PubMedCrossRefGoogle Scholar
  17. 17.
    •• Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214–23. A GWAS study in AAV which discusses different genetic associations between GPA and MPA..PubMedCrossRefGoogle Scholar
  18. 18.
    Kain R, Exner M, Brandes R, et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med. 2008;14(10):1088–96.PubMedCrossRefGoogle Scholar
  19. 19.
    Kain R, Matsui K, Exner M, et al. A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J Exp Med. 1995;181(2):585–97.PubMedCrossRefGoogle Scholar
  20. 20.
    Kain R, Tadema H, McKinney EF, et al. High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. J Am Soc Nephrol. 2012;23(3):556–66.PubMedCrossRefGoogle Scholar
  21. 21.
    Roth AJ, Brown MC, Smith RN, et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol. 2012;23(3):545–55.PubMedCrossRefGoogle Scholar
  22. 22.
    Kain R, Rees AJ. What is the evidence for antibodies to LAMP-2 in the pathogenesis of ANCA associated small vessel vasculitis? Curr Opin Rheumatol. 2013;25(1):26–34.PubMedCrossRefGoogle Scholar
  23. 23.
    Stone JH, Merkle PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associate vasculitis. N Engl J Med. 2010;363(3):221–32.PubMedCrossRefGoogle Scholar
  24. 24.
    Popa ER, Stegeman CA, Bos NA, et al. Differential B-and T-cell activation in Wegener’s granulomatosis. J Allergy Clin Immunol. 1999;103(5):885–94.PubMedCrossRefGoogle Scholar
  25. 25.
    Wilde B, Thewissen M, Damoiseaux J et al. Regulatory B cells in ANCA-associated vasculitis. Ann Rheum Dis 2013 [Epub ahead of print]Google Scholar
  26. 26.
    Eriksson P, Sandell C, Backteman K, et al. B cell abnormalities in Wegener’s granulomatosis and microscopic polyangiitis: role of CD25 + −expressing B cells. J Rheumatol. 2010;37(10):2086–95.PubMedCrossRefGoogle Scholar
  27. 27.
    Holden NJ, Williams JM, Morgan MD, et al. ANCA-stimulated neutrophils release BLys and promote B cell survival: a clinically relevant cellular process. Ann Rheum Dis. 2011;70:2229–33.PubMedCrossRefGoogle Scholar
  28. 28.
    Bader L, Koldingsnes W, Nossent J. B-lymphocyte activating factor levels are increased in patients with Wegener's granulomatosis and inversely correlated with ANCA titer. Clin Rheumatol. 2010;29(9):1031–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Krumbholz M, Specks U, Wick M, et al. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun. 2005;25(4):298–302.PubMedCrossRefGoogle Scholar
  30. 30.
    Cartin-Ceba R, Golbin J, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): a single-center ten-year experience. Arthritis Rheum. 2012;64(11):3770–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Wilde B, Thewissen M, Deamoiseaux J, et al. T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells? Arthritis Res Ther. 2010;12(1):204.PubMedCrossRefGoogle Scholar
  32. 32.
    McKinney EF, Lyons PA, Carr EJ. A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med. 2010;16(5):586–91.PubMedCrossRefGoogle Scholar
  33. 33.
    Morgan MD, Day CJ, Piper KP, et al. Patients with Wegener’s granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells. Immunology. 2010;130(1):64–73.PubMedCrossRefGoogle Scholar
  34. 34.
    Xiao H, Schreiber A, Heeringa P, et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol. 2007;170:52–64.PubMedCrossRefGoogle Scholar
  35. 35.
    Schreiber A, Xiao H, Jeannette, et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol. 2009;20:289–98.PubMedCrossRefGoogle Scholar
  36. 36.
    Yuan J, Gou SJ, Huang J, et al. C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res Ther. 2012;14(3):R140.PubMedCrossRefGoogle Scholar
  37. 37.
    Gou SJ, Yuan J, Chen M, et al. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2013;83:129–37.PubMedCrossRefGoogle Scholar
  38. 38.
    Lieberthal JG, Cuthbertson D, Carette S, et al. Urinary biomarkers in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol. 2013 May;40(5):674–83.PubMedCrossRefGoogle Scholar
  39. 39.
    Ohlsson S, Bakoush O, Tencer J, et al. Monocyte chemoattractant protein 1 is a prognostic marker in ANCA-associated small vessel vasculitis. Mediators Inflamm. 2009;2009:584916.PubMedCrossRefGoogle Scholar
  40. 40.
    Tomasson G, Lavalley M, Tanriverdi K, et al. Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis. J Rheumatol. 2011;38(6):1048–54.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of RheumatologyHospital for Special SurgeryNew YorkUSA

Personalised recommendations